Research ArticleCancer

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

See allHide authors and affiliations

Science Translational Medicine  08 Nov 2017:
Vol. 9, Issue 415, eaao4307
DOI: 10.1126/scitranslmed.aao4307

Article Information

vol. 9 no. 415

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication July 19, 2017
  • Accepted for publication October 11, 2017
  • .

Author Information

  1. Monique B. Nilsson1,
  2. Huiying Sun1,
  3. Lixia Diao2,
  4. Pan Tong2,
  5. Diane Liu3,
  6. Lerong Li2,
  7. Youhong Fan1,
  8. Alissa Poteete1,
  9. Seung-Oe Lim4,
  10. Kathryn Howells5,
  11. Vincent Haddad5,
  12. Daniel Gomez6,
  13. Hai Tran1,
  14. Guillermo Armaiz Pena7,
  15. Lecia V. Sequist8,
  16. James C. Yang9,
  17. Jing Wang2,
  18. Edward S. Kim10,
  19. Roy S. Herbst11,
  20. J. Jack Lee3,
  21. Waun Ki Hong1,
  22. Ignacio Wistuba1,12,
  23. Mien-Chie Hung4,
  24. Anil K. Sood7 and
  25. John V. Heymach1,*
  1. 1Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  2. 2Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  3. 3Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  4. 4Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  5. 5AstraZeneca, Melbourn, SG8 6EE, UK.
  6. 6Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  7. 7Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  8. 8Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
  9. 9Graduate Institute of Oncology, National Taiwan University and National Taiwan University Hospital, Taipei City 100, Taiwan.
  10. 10Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute Carolinas HealthCare System, Charlotte, NC 28204, USA.
  11. 11Section of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, Yale, New Haven, CT 06510, USA.
  12. 12Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  1. *Corresponding author. Email: jheymach{at}mdanderson.org

Altmetric

Article usage

Article usage: November 2017 to April 2021

AbstractFullPdf
Nov 20171285316082574
Dec 201779059206
Jan 2018150166113
Feb 201847053110
Mar 20183802799
Apr 20182952644
May 20182642348
Jun 20182781946
Jul 20182101628
Aug 20181293324
Sep 20181061622
Oct 20181253018
Nov 20183617857
Dec 20180210112
Jan 2019217586
Feb 20191221057
Mar 2019926474
Apr 2019727550
May 2019529350
Jun 2019819563
Jul 2019823948
Aug 2019443054
Sep 2019845140
Oct 20191040468
Nov 2019925839
Dec 2019517539
Jan 20201211448
Feb 202047869
Mar 202036443
Apr 202046662
May 2020513144
Jun 202006128
Jul 202074541
Aug 202016539
Sep 202078531
Oct 202029647
Nov 202027628
Dec 202049038
Jan 2021212254
Feb 202136325
Mar 202128325
Apr 202114727

Stay Connected to Science Translational Medicine

Navigate This Article